Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?
- PMID: 21822526
- DOI: 10.5482/ha-1173
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?
Abstract
Venous thromboembolism (VTE) is a common complication in patients with cancer that causes significant morbidity and mortality. Several patient-, tumour- and treatment-related risk factors for VTE in cancer patients have been identified. An effective and safe thromboprophylaxis in cancer patients at high risk of VTE is desirable. Recently, the identification of potential biomarkers and the development of risk scoring models for prediction of cancer-associated VTE have been published. Whether primary VTE prophylaxis based on risk assessment through these biomarkers and risk prediction models might be useful, is currently not yet known. However, thromboprophylaxis is clearly indicated in high-risk situations. While VTE prophylaxis is recommended in cancer patients undergoing surgery and in hospitalised patients with acute disease, studies in ambulatory cancer patients are still rare and evidence for primary VTE prophylaxis is currently limited. In this review, risk factors associated with VTE in cancer patients and current approaches of thromboprophylaxis in different settings, specifically in ambulatory cancer patients are subjected to a critical evaluation.
Similar articles
-
Risk assessment models for cancer-associated venous thromboembolism.Cancer. 2012 Jul 15;118(14):3468-76. doi: 10.1002/cncr.26597. Epub 2011 Nov 15. Cancer. 2012. PMID: 22086826
-
Epidemiology, risk and outcomes of venous thromboembolism in cancer.Hamostaseologie. 2012;32(2):115-25. doi: 10.5482/ha-1170. Epub 2011 Oct 5. Hamostaseologie. 2012. PMID: 21971578 Review.
-
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.Thromb Haemost. 2012 Dec;108(6):1042-8. doi: 10.1160/TH12-04-0241. Epub 2012 Jul 26. Thromb Haemost. 2012. PMID: 22836491 Review.
-
Primary venous thromboembolism prophylaxis in ambulatory cancer patients.Ann Pharmacother. 2013 Feb;47(2):198-209. doi: 10.1345/aph.1R335. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386067 Review.
-
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.Thromb Haemost. 2010 Apr;103(4):736-48. doi: 10.1160/TH09-09-0667. Epub 2010 Feb 2. Thromb Haemost. 2010. PMID: 20135072
Cited by
-
Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.Converg Sci Phys Oncol. 2017 Jun;3(2):023001. doi: 10.1088/2057-1739/aa6c05. Epub 2017 May 17. Converg Sci Phys Oncol. 2017. PMID: 29081989 Free PMC article.
-
Prevenção de tromboembolismo venoso em hospital com perfil oncológico: como melhorá-la?J Vasc Bras. 2016 Jul-Sep;15(3):189-196. doi: 10.1590/1677-5449.003216. J Vasc Bras. 2016. PMID: 29930589 Free PMC article. Portuguese.
-
Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review.J Thromb Thrombolysis. 2013 Jan;35(1):67-80. doi: 10.1007/s11239-012-0780-0. J Thromb Thrombolysis. 2013. PMID: 22826096 Review.
-
Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors.Cureus. 2022 Mar 29;14(3):e23624. doi: 10.7759/cureus.23624. eCollection 2022 Mar. Cureus. 2022. PMID: 35386484 Free PMC article.
-
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art.Front Cardiovasc Med. 2015 Jul 14;2:30. doi: 10.3389/fcvm.2015.00030. eCollection 2015. Front Cardiovasc Med. 2015. PMID: 26664901 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
